Brensocatib Market Growth Outlook Driven by Innovation and Expanding Therapeutic Applications
Brensocatib Market Overview Brensocatib market dynamics are evolving rapidly with the introduction of BRINSUPRI (brensocatib), a small molecule, once-daily, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1). It is indicated for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adult and pediatric patients aged 12 years and older. The therapy is specifically designed to inhibit the activation of neutrophil serine proteases, which are key contributors to chronic airway inflammation in NCFB. This mechanism positions Brensocatib as a targeted and innovative treatment option in a space that previously had limited therapeutic advancements. Beyond its approved use, brensocatib is also under evaluation for other neutrophil-mediated diseases, expanding its potential market reach. The report highlights Brensocatib sales , key growth drivers such as rising disease awareness and unmet clinical needs, as well as barriers including regulatory challenges and competition....